NIH Launches Human Trials for Groundbreaking Lassa Fever Vaccine
NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...
Sierra Sun Times1d
NIH-Sponsored Trial of Lassa Vaccine Opens - Viral Hemorrhagic Disease Can be Fatal & Causes Permanent Hearing Loss
NIH-Sponsored Trial of Lassa Vaccine Opens - Viral Hemorrhagic Disease Can be Fatal & Causes Permanent Hearing Loss ...
Houston Public Media9d
NIH cuts funding for vaccine-hesitancy research. mRNA research may be next
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...
Independent Journal Review7d
Check Out The Family Ties Of House Dem Championing Status Quo At NIH
A Democratic member of Congress has emerged as a vocal defender of the status quo at the National Institutes of ...
Health eCareers on MSN1d
How Infectious Disease Doctors Can Keep Up in a Rapidly Evolving Field
How Infectious Disease Doctors Can Keep Up in a Rapidly Evolving Field As with most areas of medicine, advances in infectious diseases are accelerating at a rapid clip, and it’s understandable that as ...
Corvus Pharmaceuticals announces initiation of Phase 2 trial of soquelitinib
Corvus Pharmaceuticals (CRVS) announced that the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes ...
Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers - Criteria May Help Guide Treatment of Dermatitis
Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers - Criteria May Help Guide Treatment of Dermatitis ...
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be ...
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased ...
The Daily Signal8d
Check Out the Family Ties of House Dem Championing Status Quo at NIH
DAILY CALLER NEWS FOUNDATION—A Democratic member of Congress has emerged as a vocal defender of the status quo at the National Institutes ... Institute of Allergy and Infectious Diseases ...